Case Report: First Case of Non-restrictive Ventricular Septal Defect With Congestive Heart Failure in a Chinese Han Male Infant Carrying a Class II Chromosome 17p13.3 Microduplication

Yung-Yu Yang, Chun-Ting Liu, Li-Fan Pai, Chih-Fen Hu, Shyi-Jou Chen and Wan-Fu Hsu

Chromosome 17p13.3 microduplication syndrome is considered a multisystem disorder that results in a wide variety of clinical manifestations including dysmorphic facial characteristics, brain structural malformations, developmental restriction, growth restriction, and neurocognitive disorders. The two major classes of chromosome 17p13.3 microduplication, which have different clinical presentations, are associated with specific genetic regions. Among the various known phenotypes, scattered cases with congenital heart disease (CHD) have been reported for both classes of chromosome 17p13.3 microduplication syndrome. Unfortunately, there is insufficient understanding of the correlation between chromosome anomaly induced alterations in gene expression and aberrant cardiac development, and thus early diagnosis of CHD among patients with chromosome 17p13.3 microduplication is difficult without routine prenatal cardiac assessment. One such congenital heart anomalies known to affect a substantial number of newborns worldwide is ventricular septal defect (VSD), which has been found in 17p13.3 microduplication carriers, and seems to sometimes undergo spontaneous closure. We report an unprecedented case of moderate sized perimembranous-outlet VSD and congestive heart failure (CHF) in a Chinese Han male infant with a class II chromosome 17p13.3 microduplication. Despite the fact that cytogenic testing and fetal echocardiography confirmed a 249-Kb chromosome duplication within 17p13.3 that encompassed the PAFAH1B1 gene and showed the presence of VSD during prenatal period, this patient still developed a range of symptoms including sustained prolonged feeding, dyspnea, diaphoresis and retarded growth. A physical examination indicated hepatomegaly and a grade III/VI pan-systolic murmur along the left upper sternal border. Laboratory testing showed a high serum pro–B-type natriuretic peptide (pro-BNP). Imaging studies revealed cardiomegaly and a persistent VSD with related pulmonary stenosis. Since the clinical findings were compatible with CHF, we provided mainline
treatment with digoxin, captopril, and furosemide, as well as fluid restriction. Despite sustained poor weight gain, the feeding behavior and the respiratory conditions of the patient improved gradually. This case report and literature review suggest that patients carrying chromosome 17p13.3 microduplication who have VSD may have an increased risk of developing CHF as young infants and hence a comprehensive cardiac evaluation is warranted to allow the early diagnosis and management of any severe heart anomalies.

**Keywords:** congenital heart disease, congestive heart failure, chromosome 17p13.3 microduplication, microarray comparative genomic hybridization, ventricular septal defect

**INTRODUCTION**

17p13.3 microduplication syndrome, which seem to be created by non-allelic homologous recombination, is a rare genetic disorder and only 40 cases have been documented since it was first reported in 2009 (1, 2). Microduplications affecting 17p13.3 are categorized into two classes according to the affected genes within the duplication (3). In contrast to the absolute absence of PAFAH1B1 duplications in class I 17p13.3 microduplications, an amplified PAFAH1B1 gene and the possible concurrent duplication of the YWHAE gene or the CRK gene within the 17p13.3 region have been found in class II 17p13.3 microduplications (3). Class I microduplications are associated with learning disabilities, autism, overgrowth tendency, facial dysmorphism, and developmental delays (1, 3, 4). Class II microduplications otherwise lead to mild brain malformations, hypotonia and developmental delays (1, 3, 4). Despite early identification of this rearrangement being possible using advanced cytogenetic analysis techniques such as microarray comparative genomic hybridization (aCGH) (5, 6), a comprehensive understanding of all the clinical presentations brought about by chromosome17p13.3 microduplication and their genotype-phenotype correlations are lacking. This has limited the development of effective treatments. CHD in patients carrying chromosome 17p13.3 microduplication is particularly under-recognized due to its sporadic nature and poor in-depth descriptions of relevant cardiovascular evaluation details (5, 7).

CHD is one of the most commonly diagnosed congenital disorder and detrimentally impacts the health of 0.8% of live births worldwide (8, 9). Among the various types of CHDs, VSD accounts for a large proportion of congenital heart malformations (up to 40%), and has been reported to have a prevalence of 5.3% among newborns based on color doppler echocardiography (10). It is well-established that many VSD patients are asymptomatic and that their cardiac defect spontaneously closes without long-term effects (10). Nevertheless, because pulmonary vascular resistance during the early neonatal period is diminished, infants with non-restrictive VSDs can develop CHF due to persistent excessive pulmonary blood flow via the left-to-right interventricular shunt (10). This can lead to mortality unless there is timely surgical intervention (11).

We report a 2-month-old Chinese male infant with de novo microduplication of 17p13.3 encompassing PAFAH1B1 who presented with feeding difficulties and restricted growth. In addition to a pansystolic murmur and hepatomegaly, laboratory tests and an echocardiogram showed elevated pro-BNP and a moderate-sized perimembranous-outlet VSD with related pulmonary stenosis. Our patient demonstrated a quite severe cardiac defect complicated by CHF. This is the first such reported case in an Asian population. We present this case to raise clinical awareness and broaden our understanding of the severe heart anomalies that occur in patients carrying a chromosome 17 microduplication.

**CASE PRESENTATION**

A 2-month-old male infant was admitted with frequent vomiting during feeding, diaphoresis and dyspnea with subcostal retractions for 2 weeks. The patient had been bottle-fed with formula milk per feed (120 ml) four times daily (total fluid 129 ml/kg/24 h), and had received all appropriate vaccinations. However, prolonged feeding (more than 1 h per meal), with dysphagia and intermittent vomiting, and a decreased urine output with reddish-orange staining on diapers, had been present for about 2 weeks. The second child of non-consanguineous healthy Han Chinese parents, he was born at full term by vaginal delivery (Appar scores of 8 and 9 at 1 and 5 min, respectively). His birth weight was 3,140 gm (10th−50th percentile), his height was 47.5 cm (10th−50th percentile), and his occipital frontal circumference was 35.5 cm (>90th percentile).

His mother, a 34-year-old multigravida, had been diagnosed with hyperthyroidism before pregnancy and had been treated with propylthiouracil 50 mg once daily. Both the father and the older sister of the patient were healthy. After being informed of a 1 in 61 chance of having a baby with Down syndrome based on her maternal serum screening, his mother had undergone amniocentesis at week 19 of gestation, the G-banded karyograms of the patient were normal (46,XY), however cytogenetic analysis of the fetal DNA by aCGH revealed a 0.249-Mb duplication that encompassed PAFAH1B1, but not another candidate gene YWHAE (Figure 1A). Since oligonucleotide-based microarray analyses of both his parents gave normal profiles (Figures 1B,C) that encompassed PAFAH1B1, de novo chromosomal rearrangement was likely to be the cause of the chromosome 17 microduplication. Fetal MRI performed at week 28 of gestation revealed no significant abnormalities,
whereas a fetal cardiac anomaly scan at week 34 of gestation found a 0.3-cm VSD.

The patient was born at 39 + 2 weeks of gestation via spontaneous vaginal delivery without fetal distress, and no obvious facial dysmorphism was documented in the newborn physical examination. After birth, due to shortness of breath with oxygen desaturation (SpO$_2$ 85–90%) during feeding, the patient was admitted to neonatal intensive care for empirical antibiotic treatment under suspicion of neonatal sepsis. We discontinued antibiotics after two blood cultures separated by
adequate nutrition supplementation, we gradually titrated the weight loss.

Infant presenting with frequent vomiting, lethargy and body infantile hypertrophic pyloric stenosis, a likely cause of an amount of formula milk fed to the patient (30 kcal/ounce) until (was performed. This showed subtle corpus callosum hypoplasia 17p13.3 microduplications, and therefore cranial sonography malformations may exist in patients carrying chromosome LA/Ao 1.5). An intramuscular palivizumab injection was given once per month to prevent respiratory syncytial virus infection. Developmental delay among patients carrying a chromosome 17p13.3 microduplication is common and therefore we consulted a pediatric neurologist. No marked abnormalities were noted after stringent evaluation.

The patient was discharged from the hospital given the refusal of surgical intervention by his mother. Nevertheless, his mother changed her mind shortly after, and therefore the infant underwent surgical closure of the VSD at another medical center in Northern Taiwan. According to his mother, the infant was in a stable condition after the operation. He is 7-month-old now and is regularly followed up at the pediatric cardiology/neurology outpatient department without any report of development delay.

FIGURE 2 | Anterior and lateral views of the patient’s face (A,B) revealing dolichocephaly, a down-turned mouth (indicated by the white arrow), a triangular face and diaphoresis on the forehead.

Serum laboratory testing revealed elevated pro-BNP (3,119 pg/ml, reference range 5–1,121 pg/ml) without electrolyte imbalance. Chest radiography showed cardiomegaly (cardiothoracic ratio 0.66) and pulmonary congestion (Figure 3A). An echocardiogram on admission identified a perimembranous-outlet VSD (0.471 cm) with related pulmonary stenosis and a dilated left-sided heart with mild-to-moderate mitral valve regurgitation (Ejection Fraction 86.4%, and Left Atrial to Aortic Root Ratio 1.84) (Figures 4A, B). Cardiac auscultation and abdomen palpitation revealed a grade III/VI pan-systolic murmur over left upper sternal border and hepatomegaly at 2.5 finger-breaths below the costal margin. Otherwise, no significant developmental delay or neurobehavioral abnormalities were found.

Serum laboratory testing revealed elevated pro-BNP (3,119 pg/ml, reference range 5–1,121 pg/ml) without electrolyte imbalance. Chest radiography showed cardiomegaly (cardiothoracic ratio 0.66) and pulmonary congestion (Figure 3A). An echocardiogram on admission identified a perimembranous-outlet VSD (0.471 cm) with related pulmonary stenosis and a dilated left-sided heart with mild-to-moderate mitral valve regurgitation (Ejection Fraction 86.4%, and Left Atrial to Aortic Root Ratio 1.84) (Figures 4A, B). Cardiac auscultation and abdomen palpitation revealed a grade III/VI pan-systolic murmur over left upper sternal border and hepatomegaly at 2.5 finger-breaths below the costal margin. Otherwise, no significant developmental delay or neurobehavioral abnormalities were found.

Figure 3B. Furthermore, abdomen sonography excluded infantile hypertrophic pyloric stenosis, a likely cause of an infant presenting with frequent vomiting, lethargy and body weight loss.

To strike a balance between fluid overload control and adequate nutrition supplementation, we gradually titrated the amount of formula milk fed to the patient (30 kcal/ounce) until his daily caloric intake reached 150 kcal/kg/day, while at the same time the daily total fluid amount given to the patient was limited, to not exceeding 150 mg/kg/day. An oral form loop diuretic, furosemide (2 mg/kg/dose), was given to the patient twice daily in order to maintain an adequate urine output of 2 ml/kg/hr. Heart failure medications, including digoxin (4 mcg/kg/dose) and captopril (0.2 mg/kg/dose), were given to the infant twice daily. In addition, we used domperidone (0.25 mg/kg/dose) every 8 h to provide relief from vomiting and reduced difficulty with feeding. During admission, plasma levels of pro-BNP and electrolytes, as well as chest radiography images, were obtained regularly to evaluate the efficacy of the anticongestive treatment. Despite sustained perihilar infiltrates and an increased cardiothoracic ratio, as shown in chest x-ray images, the heart failure symptoms improved gradually and were accompanied by clinical evidence of an alleviation of the patient's dyspnea. There was also a gradual improvement in both oral intake and urine output, together with a steadily decrease in plasma pro-BNP and an absence of electrolyte imbalance. Repeated echocardiograms after treatment revealed that the size of the VSD was unchanged at 0.471 cm, and this was accompanied by a subtle decrease in the left atrial to aortic root ratio (Ejection Fraction 85%, LA/Ao 1.5). An intramuscular palivizumab injection was given once per month to prevent respiratory syncytial virus infection. Developmental delay among patients carrying a chromosome 17p13.3 microduplication is common and therefore we consulted a pediatric neurologist. No marked abnormalities were noted after stringent evaluation.

The patient was discharged from the hospital given the refusal of surgical intervention by his mother. Nevertheless, his mother changed her mind shortly after, and therefore the infant underwent surgical closure of the VSD at another medical center in Northern Taiwan. According to his mother, the infant was in a stable condition after the operation. He is 7-month-old now and is regularly followed up at the pediatric cardiology/neurology outpatient department without any report of development delay.

DISCUSSION

Among a wide spectrum of phenotypes, congenital heart disease is rare for both classes of chromosome 17p13.3 microduplication syndrome (5). Specifically, reports have identified patent ductus arteriosus, mitral valve prolapse, aortic dilation and aortic stenosis as common among class I 17p13.3 microduplication carriers, while patient foramen ovale and spontaneously closing VSD have been identified among class II individuals (4, 5, 7, 12). Cytogenetic testing of probands and their parents has proved that these gene amplifications usually originate by de novo chromosomal rearrangement, including ours. In our case the amplification is a plausible cause of this patient’s CHD (2). Notably, distinct from spontaneously closing VSD, which was asymptomatic in the case described by Avela et al. (7), it is unprecedented that our patient, with the smallest duplicated chromosome fragment of all existing cases, should suffer from a non-restrictive VSD and then subsequently develop CHF.
Distinct from the signs and symptoms of heart failure in adults, infants with CHF suffer from fatigue, difficulty in feeding, shortness of breath, diaphoresis, retarded growth and retarded development (13–15). Physical findings may include tachypnea or dyspnea with grunting and retractions, tachycardia, a gallop rhythm and hepatomegaly (13, 16). Electrocardiogram and chest X-ray images can exclude cardiac arrhythmia and provide evidence supporting CHF, including cardiomegaly (cardiothoracic ratio > 0.6 cm on a posterior anterior film), pulmonary edema and pleural effusion (14, 17). B-type natriuretic peptide (BNP) and N-terminal pro BNP assays are widely used and have the clinical benefit of excluding non-cardiac causes of respiratory symptoms and fluid retention, of assessing treatment efficacy, of predicting future hospitalization and of pinpointing mortality risk (18–20). Cardiac troponin I and T are also useful biomarkers that can reflect myocyte injury, but they are less specific to heart failure because elevated cardiac enzyme levels are often present in other clinical scenarios including myocarditis or ischemic heart disease (13, 14).

Monitoring of electrolyte levels, liver function and renal function are crucial for identifying impairment of vital organs due to poor perfusion; they can also serve as indicators during diuretic dose adjustment (14). Additionally, a complete blood count and thyroid function testing may reveal the presence of aggravating factors for heart failure, including anemia, hyperthyroidism or hypothyroidism (14). Both the clinical symptoms and objective findings of our patient were consistent with CHF; it should be noted that electrolyte imbalance and/or vital organ impairment were not present on admission.

Neonates with CHDs, including VSDs, complete atrioventricular canal defects, patent ductus arteriosus and aortopulmonary windows, are susceptible to develop CHF when a persistent left to right shunt and increased pulmonary blood flow due to reduced pulmonary resistance are present (10, 14). Nevertheless, the correlation between chromosomal duplication and cardiac structural abnormalities remains unclear given the low number of confirmed cases. Based on various studies, involving animal models, we suggest that alterations...
in the expression of YWHAE and PAFAH1B may result in a
genetic predisposition toward heart failure among 17p13.3
microduplications carriers (21–26).

Both trabeculation and compaction are essential processes
during cardiogenesis (27). The trabecular myocardium makes
up the majority of the embryonic ventricles initially, and
a gradual replacement of the myocardial trabeculum by
a compact myocardium occurs during the later stages of
heart development (21, 27, 28). Mutation of genes regulating
ventricular growth and maturation seem to lead to CHD and
even heart failure (28). Previous studies have shown that YWHAE
encodes 14-3-3ε, a protein that specifically binds to ubiquitous
phosphoserine/threonines and is crucial for promoting human
endothelial cell survival and regulating ventricular myocardium
compaction. It has been shown to do this in a mouse model
by modulating the cardiomyocyte cell cycle (21, 22). In Kosaka
et al., which explored heart development in mice carrying a
homozygous 14-3-3ε deletion, similar histological characteristics
to left ventricular non-compaction cardiomyopathy in humans
were found. Furthermore, it was shown that defective 14-3-3ε
functioning is detrimental to interventricular septum
maturation resulting in concomitant VSDs in ~60% of 14-
3-3ε-null mice (21). Despite an unclear role for the 14-3-3ε
protein in ventricular morphogenesis, the presence of
cell cycle arrest, was detectable. This was associated with
upregulation of the G1/S phase transition inhibitor p27Kip1
and downregulation of cyclin E1 in the 14-3-3ε-deficient
cardiomyocytes, providing a tentative explanation for the
phenotype (21).

PAFAH1B1 is another candidate gene that has been postulated
to impact cardiovascular maturation and this seems to occur via
regulation of cardiac-specific microRNAs. The protein encoded
by PAFAH1B1, platelet-activating factor acetylhydrolase IB
subunit alpha, ensures appropriate cell migration by stabilizing
dynein-dependent microtubule dynamics (29). Rao et al.
demonstrated that cardiac-specific deletion of the miRNA-
processing enzyme Dicer results in dilated cardiomyopathy
and premature death (23). Furthermore, microRNA-125b, a
cardiomyocyte maturation inducer, seems to protect murine
cardiac myocytes against myocardium ischemia/reperfusion
injury by suppressing the pro-apoptotic genes p53 and Bak1
(24). Moreover, defective mitochondrial morphology and
dysregulation of fatty acid metabolism were found to be present
in the hearts of miR-125b-1 knockout mice resulting in cardiac
hypertrophy and high prenatal lethality (25). Intriguingly,
in addition to the identification of PAFAH1B1 as a target of
miR-139-5p by proteomics analysis, the expression of
Pafah1b1 protein is known to be upregulated after inhibition of
microRNA-125b (25, 26). While the direct influence of Pafah1b1
protein on cardiovascular development remains open, the
aforementioned findings imply that it potentially can hamper
normal cardiac morphogenesis. The aCGH analysis carried
out on our patient only showed the presence of a PAFAH1B1
amplification and confirmed that the YWHAE gene had a normal
copy number. We hypothesize that the CHF symptoms, which
originated from non-restrictive VSD, may be aggravated by
17p13 microduplications encompassing PAFAH1B1. This seems
to result in an increased susceptibility to cardiac hypertrophy
and thus compromised cardiac energy production.

Apart from influencing cardiomyocyte maturation, increased
expression of PAFAH1B1 and its protein LIS1 have been shown to
induce subtle brain malformations, to retard growth and
to cause moderate/severe developmental delay (4). Among the
documented brain abnormalities in patients with class II 17p13.3
microduplication syndrome, a significant number of cases have a
hypoplastic/dysplastic corpus callosum, a smaller occipital cortex
and a mild cerebellum volume loss (1, 4). Mild corpus callosum
hypoplasia was detected in our patient by cranial ultrasound
imaging rather than more widely used brain MRI (1, 4, 7, 12),
regular neurological assessments of similar cases is suggested.

The facial characteristics present in this case are somewhat
similar to the ones described in another patient with class II
17p13.3 microduplication (7). Nevertheless, it remains
challenging when trying to differentiate the two classes of 17p13.3
microduplication syndrome based on dysmorphic facial features
because there are several unsolved problems. Firstly, subtle facial
dysmorphism tends to be misrecognized/neglected when an
experienced clinical geneticist is not available; therefore whether
existing reports describe accurately the facial characteristics of
each patient is uncertain. Secondly, despite the fact that prior
studies have shown a strong correlation between dysmorphic
facial traits and changes affecting the YWHAE/CRK genes
(3, 5, 30, 31), evidence confirming the genetic impact of
PAFAH1B1 amplification and a normal YWHAE genotype on
the facial development of patients remains lacking. Further
investigations are required to decipher the causative factor(s)
behind facial dysmorphism in patients with chromosome
17p13.3 microduplication.

In conclusion, we describe for the first time a case involving
a Chinese Han male infant with a class II chromosome
17p13.3 microduplication who developed non-restrictive
VSD and significant CHF. In addition to the previously
identified phenotypes associated with chromosome 17p13.3
microduplication, including brain structural anomalies and
facial dysmorphism, pediatricians should be aware of the
possibility of severe heart structural defects and related
complications when patients carry 17p13.3 microduplications.
Moreover, the present case highlights the role of aCGH in
detecting chromosomal anomalies in fetuses with CHD, for
those patients have been shown to carry a higher risk of
additional extracardiac malformations (32). Compared with
conventional karyotyping, high resolution aCGH enables more
accurate detection of copy number variants within the genome
(32). The case report also echoes the comments made by
Ho et al., who emphasized the importance of comprehensive
non-invasive cardiac evaluations when patients have a 17p13.3
microduplication (5). There has been increased application of
early diagnosis by prenatal cyto genetic analysis and fetal cardiac
ultrasound scanning is now more common. This meant that
our patient received timely treatment and did not undergo
progressive deterioration of his heart and possible heart failure.
This case report broadens our understanding of congenital heart
disease among chromosome 17p13.3 microduplication carriers,
while at the same time emphasizing the need for additional
research to unravel the underlying pathogenesis associated with chromosome 17p13.3 microduplications.

DATA AVAILABILITY STATEMENT

The original contributions presented in the study are included in the article/supplementary material, further inquiries can be directed to the corresponding author/s.

ETHICS STATEMENT

The studies involving human participants were reviewed and approved by Tri-Service General Hospital. Written informed consent to participate in this study was provided by the participants’ legal guardian/next of kin. Written informed consent was obtained from the minor(s)’ legal guardian/next of kin for the publication of any potentially identifiable images or data included in this article.

REFERENCES

1. Curry CJ, Rosenfeld JA, Grant E, Gripp KW, Anderson C, Aysworth AS, et al. The duplication 17p13.3 phenotype: analysis of 21 families delineates developmental, behavioral and brain abnormalities, and rare variant phenotypes. *Am J Med Genet A.* (2013) 161A:1833–52. doi: 10.1002/ajmg.a.35996
2. Blazejewski SM, Bennison SA, Smith TH, Toyo-Oka K. Neurodevelopmental genetic diseases associated with microdeletions and microduplications of chromosome 17p13.3. *Front Genet.* (2018) 9:80. doi: 10.3389/fgene.2018.00080
3. Bruno DL, Anderlid BM, Lindstrand A, van Ravenswaaij-Arts C, Ganesamoorthy D, Lundin J, et al. Further molecular and clinical delineation of co-locating 17p13.3 microdeletions and microduplications that show distinctive phenotypes. *J Med Genet.* (2010) 47:299–311. doi: 10.1136/jmg.2009.069906
4. Bi W, Sapir T, Shchelochkov OA, Zhang F, Withers MA, Hunter JV, et al. Increased L115 expression affects human and mouse brain development. *Nat Genet.* (2009) 41:168–77. doi: 10.1038/ng.302
5. Ho AC, Liu AP, Lui KS, Tang WE, Chan KY, Lau EY, et al. A newborn with a 790 kb chromosome 17p13.3 microduplication presenting with aortic stenosis, microcephaly and dysmorphic facial features - is cardiac assessment necessary for all patients with 17p13.3 microduplication? *Eur J Med Genet.* (2012) 55:758–62. doi: 10.1016/j.ejmg.2012.09.011
6. Chen CP, Chang TY, Guo WY, Wu PC, Wang IK, Chern SR, et al. Chromosome 17p13.3 deletion syndrome: aCGH characterization, prenatal findings and diagnosis, and literature review. *Gene.* (2013) 532:152–9. doi: 10.1016/j.gene.2013.09.044
7. Avela K, Aktan-Collan K, Horelli-Kuitunen N, Knuutila S, Somer M. A microduplication on chromosome 17p13.3 including the PAFAH1B1 (LIS1) gene. *Am J Med Genet A.* (2011) 155A:A857–9. doi: 10.1002/ajmg.a.33944
8. Bernier PL, Stefanescu A, Samoukovic G, Tchervenkov CI. The challenge of congenital heart disease worldwide: epidemiologic and demographic facts. *Semin Thorac Cardiovasc Surg Pediatr Card Surg Annu.* (2010) 13:26–34. doi: 10.1053/j.pcsu.2010.02.005
9. Bouma BJ, Mudder BJ. Changing landscape of congenital heart disease. *Circ Res.* (2017) 120:908–22. doi: 10.1161/CIRCRESAHA.116.309302
10. Penny DJ, Vick GW III. Ventricular septal defect. *Lancet.* (2011) 377:1103–12. doi: 10.1016/S0140-6736(10)61339-6
11. Sommers C, Nagel BH, Neudorf U, Schmaltz AA. [Congestive heart failure in childhood. An epidemiologic study]. *Herz.* (2005) 30:652–62. doi: 10.1007/s00059-005-2596-6
12. Roos L, Jonch AE, Kjaergaard S, Taudorf K, Simonsen H, Hamborg-Petersen B, et al. A new microduplication syndrome encompassing the region of the Miller-Dieker (17p13 deletion) syndrome. *J Med Genet.* (2009) 46:703–10. doi: 10.1136/jmg.2008.065094
13. Rossano JW, Shaddy RE. Heart failure in children: etiology and treatment. *J Pediatr.* (2014) 165:228–33. doi: 10.1016/j.jpeds.2014.04.055
14. Masarone D, Valente F, Rubino M, Vastarella R, Gravino R, Rea A, et al. Pediatric heart failure: a practical guide to diagnosis and management. *Pediatr Neonatol.* (2017) 58:303–12. doi: 10.1016/j.pedneo.2017.01.001
15. Nandi D, Rossano JW. Epidemiology and cost of heart failure in children. *Cardiol Young.* (2015) 25:1460–8. doi: 10.1017/S1047951115002280
16. Madriago E, Silberbach M. Heart failure in infants and children. *Pediatr Rev.* (2010) 31:4–12. doi: 10.1542/pir.31.4
17. Satou GM, Lacro RV, Chung T, Gauvreau K, Jenkins KJ. Heart size on chest x-ray as a predictor of cardiac enlargement by echocardiography in children. *Pediatr Cardiol.* (2001) 22:218–22. doi: 10.1007/s002460010207
18. Price JF, Thomas AK, Grenier M, Eidem BW, O’Brien Smith E, Denfield SW, et al. B-type natriuretic peptide predicts adverse cardiovascular events in pediatric outpatients with chronic left ventricular systolic dysfunction. *Circulation.* (2006) 114:1063–9. doi: 10.1161/CIRCULATIONAHA.105.608869
19. Auerbach SR, Richmond ME, Lamour JM, Blume ED, Addonizio LJ, Shaddy RE, et al. BNP levels predict outcome in pediatric heart failure patients: post hoc analysis of the Pediatric Carvedilol Trial. *Circ Heart Fail.* (2010) 3:606–11. doi: 10.1161/CIRCHEARTFAILURE.109.998675
20. Wong DT, George K, Wilson J, Manhivist C, McGrindle BW, Adeli K, et al. Effectiveness of serial increases in amino-terminal pro-B-type natriuretic peptide levels to indicate the need for mechanical circulatory support in children with acute decompensated heart failure. *Am J Cardiol.* (2010) 107:573–8. doi: 10.1016/j.amjcard.2010.10.015
21. Kosaka Y, Cieslik KA, Li L, Lezin G, Maguire CT, Saijoh Y, et al. 14-3-3epsilon activated receptor-delta upregulates 14-3-3 epsilon in human endothelial cells via CCAAT/enhancer binding protein-beta. *Circ Res.* (2007) 100:e59–68. doi: 10.1161/01.RES.0000260805.99076.22
22. Rao PK, Toyama Y, Chiang HR, Gupta S, Bauer M, Medvid R, et al. Loss of cardiac microRNA-mediated regulation leads to...
24. Wang X, Ha T, Zou J, Ren D, Liu L, Zhang X, et al. MicroRNA-125b protects against myocardial ischaemia/reperfusion injury via targeting p53-mediated apoptotic signalling and TRAF6. *Cardiovasc Res.* (2014) 102:385–95. doi: 10.1093/cvr/cvu044

25. Chen CY, Lee DS, Choong OK, Chang SK, Hsu T, Nicholson MW, et al. Cardiac-specific microRNA-125b deficiency induces perinatal death and cardiac hypertrophy. *Sci Rep.* (2021) 11:2377. doi: 10.1038/s41598-021-81700-y

26. Oh JG, Lee P, Gordon RE, Sahoo S, Kho C, Jeong D. Analysis of extracellular vesicle miRNA profiles in heart failure. *J Cell Mol Med.* (2020) 24:7214–27. doi: 10.1111/jcmm.15251

27. Wengrofsky P, Armenia C, Oleszak F, Kuperstein E, Rednam C, Mitre CA, et al. Left ventricular trabeculation and noncompaction cardiomyopathy: a review. *EC Clin Exp Anat.* (2019) 2:267–83.

28. Wilsbacher L, McNally EM. Genetics of cardiac developmental disorders: cardiomyocyte proliferation and growth and relevance to heart failure. *Annu Rev Pathol.* (2016) 11:395–419. doi: 10.1146/annurev-pathol-012615-044336

29. Abal M, Piel M, Bouckson-Castaing V, Mogensen M, Sibarita JB, Bornens M. Microtubule release from the centrosome in migrating cells. *J Cell Biol.* (2002) 159:731–7. doi: 10.1083/jcb.200207076

30. Ostergaard JR, Graakjaer J, Brandt C, Birkebaek NH. Further delineation of 17p13.3 microdeletion involving CRK. The effect of growth hormone treatment. *Eur J Med Genet.* (2012) 55:22–6. doi: 10.1016/j.ejmg.2011.09.004

Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher's Note: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.